What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: hypertension (n=1749). Intervention: Triple low-dose combination (triple-LDC) therapy vs. Placebo or standard-dose monotherapy. Primary outcome: systolic blood pressure reduction compared with placebo (MD -13.76, 95% CI -19.28 to -8.23).

What question did this study set out to answer?

This research evaluates the effectiveness and safety of low-dose triple antihypertensive therapy compared to placebo and standard-dose monotherapy.

June 3, 2026

Efficacy and Safety of Initial Low-Dose Triple Combination Therapy for Hypertension: A Systematic Review and Meta-Analysis

Key Result

Triple low-dose combination therapy significantly reduced systolic blood pressure by 13.76 mmHg compared with placebo (95% CI, -19.28 to -8.23) and more than doubled blood pressure control rates.

Key Points

This research evaluates the effectiveness and safety of low-dose triple antihypertensive therapy compared to placebo and standard-dose monotherapy.
Systematic review and meta-analysis of randomized controlled trials.
Identified trials compared triple-LDC therapy to placebo or standard monotherapy.
Pooled estimates calculated using random-effects models.
Triple-LDC significantly reduced systolic BP by -13.76 mmHg (95% CI, -19.28 to -8.23) and diastolic BP by -7.45 mmHg (95% CI, -10.85 to -4.04) compared to placebo.
BP control rates more than doubled with triple-LDC (RR 2.27, 95% CI, 1.37 to 3.75).
No increased adverse events reported across triple-LDC and other therapies.

Study Design

Type

Meta-Analysis (n=1,749)

Structured PICO

Does single-pill triple low-dose combination therapy reduce blood pressure compared with placebo or standard-dose monotherapy in patients with hypertension?

Population

1,749 participants across 8 randomized controlled trials evaluating triple low-dose combination therapy for hypertension.

Intervention

Single-pill triple low-dose combination (triple-LDC) antihypertensive drugs (≤50% of the standard dose per component)

Comparator

Placebo or standard-dose (SD) monotherapy

Outcome

Systolic and diastolic blood pressure reductionsurrogate

Initial low-dose triple combination therapy provides substantial blood pressure reduction compared with placebo and modest additional benefit over standard-dose monotherapy without increasing adverse events.

Main Result

Mean Difference: -13.76 (95% CI -19.28–-8.23)

Abstract

Objective: Single-pill triple low-dose combination (triple-LDC) antihypertensive drugs have become available for clinical use as an alternative initial therapy for hypertension, expanding options beyond conventional monotherapy. We evaluated the efficacy and safety of triple-LDC therapy compared with placebo or standard-dose (SD) monotherapy. Design and method: This systematic review and meta-analysis followed a prespecified PROSPERO-registered protocol and PRISMA guidelines. Randomized controlled trials comparing triple-LDC therapy (1.0 SD) and ultra-low-dose (sum of dose fraction <=1.0 SD) regimens were superior to placebo, with no differences between doses. Versus SD monotherapy, low-dose therapy was superior, whereas ultra-low-dose therapy showed comparable efficacy. Findings were consistent in sensitivity analyses. Treatment-emergent adverse events and withdrawal rates were similar across groups.Conclusions: Triple-LDC therapy provides substantial BP reduction compared with placebo and modest additional benefit over SD monotherapy without increased adverse events, supporting its role as an effective initial treatment strategy for hypertension.

AI से पूछें

Bookmark